Please login to the form below

Not currently logged in
Email:
Password:

BMS’ Q2 results beat expectations with strong performance across core therapy areas

In Q2, BMS’ revenue came in at $11.7bn, a 16% increase on the same period last year

Bristol Myers Squibb (BMS) has published its second quarter (Q2) earnings, with revenue for the quarter up by 16% from last year as the company’s strong performance beat expectations.

In Q2, BMS’ revenue came in at $11.7bn, a 16% increase on the same period last year, which had been negatively impacted by the COVID-19 pandemic.

“While COVID recovery dynamics as well as approximately $40 million in US inventory build contributed this quarter's growth, the brand's performance was largely driven by strong demand for both our core and our newly launched indications,” said David Elkins, chief financial officer of BMS.

In the US, revenues were up by 14% to $7.4bn, while international revenues increased by 18% to $4.3bn in Q2. Earnings per share (EPS) were $1.93 in the quarter, beating analyst expectations of $1.88.

Bringing in the most sales in the quarter was multiple myeloma drug Revlimid, which was up by 11% from the previous quarter, bringing in $3.2bn. Blood thinner Eliquis also performed strongly, with BMS reporting a 29% increase in the quarter to $2.7bn.

Sales of its oncology drugs Opdivo and Yervoy also increased on the same period last year, up by 16% and 38%, respectively.

“We delivered a strong quarter across each of our four therapeutic areas, including building momentum for our new product portfolio and Opdivo returning to growth,” said Giovanni Caforio, board chair and chief executive officer, BMS.

“We achieved significant clinical and regulatory milestones reflecting the hard work and dedication of our team, who together have built a portfolio of best-in-class medicines to meet the needs of patients with serious diseases.

“As we move forward, we remain focused on driving inline product performance, progressing our new launches and advancing pipeline opportunities. Our robust and diverse pipeline combined with our clinical and commercial execution strengthen our confidence in our ability to renew the portfolio and achieve sustained growth,” she added.

Article by
Lucy Parsons

29th July 2021

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...